SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Povorcitinib Enrolls First Patient in China Phase III Trial

China Medical System said its oral vitiligo drug povorcitinib has enrolled its first patient in a Phase III clinical trial in China.

INCY

Related stories